AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03247660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational strategy
Description: See information included in arm/group descriptions.
Study NCT00829348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS)
Description: 60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
Study NCT05590650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SZKJT(San-Zhong-Kui-Jian-Tang)
Description: The SZKJT samples were made and packed by Kaiser Pharmaceutical Co. Ltd. with lot number of 2019023247.
Study NCT03959241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate
Description: Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
Study NCT03959241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting on Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-15. If patients are on medications which alter the metabolism of tacrolimus (e.g.concurrent CYP3A4 inhibitors), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices and patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD.
Study NCT03959241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. Methotrexate should be dose reduced, given with leucovorin rescue, or held for complications such as severe mucositis per institutional guidelines.
Study NCT03959241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide
Description: Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
Study NCT03959241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting Day +5. Starting tacrolimus dose can be modified to account for possible drug interactions (e.g. concurrent CYP3A4 inhibitor use) according to institutional guides. Serum levels of tacrolimus will be measured at Day +7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD
Study NCT03959241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: MMF will be given at a dose of 15 mg/kg/dose ter in die (TID) (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day +5 and discontinue after the last dose on Day +35, or may be continued if active GVHD is present.
Study NCT03959241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide \[50 mg/kg ideal body weight (IBW); if actual body weight (ABW) \< IBW, use ABW\] will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day +4 post-transplant (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
Study NCT05025579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Since up in 2 min 10 repetitions active joint movement (while seated knee flexion and extension the ankle plantar and dorsal flexion , standing the hip flexion , extension the , abduction and adduction ) , treadmill for 3 minutes, 0.5 m / sec speed walk with and to adapt both warming bike 5 minutes, RPE ( Rating of Perceived exertion discoverable by exertion rate) will be 2/10 in a way was built.~As aerobic exercise, the first week will be RPE 4/10 for 10 minutes, the second week with RPE 4/10 12 minutes, the third week with RPE 4/10 14 minutes, the fourth week with RPE 4/10, 16 minutes, the fifth week with RPE 5/ 2 0 will be as 18 minutes sixth week RPA 10.6 will form was done 20 minutes of exercise .~Cooling period in the RPE 2.10 will be the 5 minute turning cycling, 5 min active range of motion exercises and stretching was done.
Study NCT00748553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (Vidaza)
Description: 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle
Study NCT03060642 — intervention group
Intervention type: DEVICE
Intervention: Tethered capsule sponge
Description: Subjects swallow a tethered capsule sponge sampling device, which is then withdrawn through the mouth after an interval of 5 minutes.
Study NCT00748553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (Abraxane)
Description: 100mg/m2 weekly for 3 weeks of each 4-week cycle
Study NCT00585923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed hole C-Tek™ Plate
Description: Fixed hole C-Tek™ Plate
Study NCT00585923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Slotted hole C-Tek™ Plate
Description: Slotted hole C-Tek™ Plate
Study NCT05827484 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous platelets rich plasma
Description: 30 ml of venous blood were drawn from the participant by means of venipuncture. The collected blood was mixed with 3 ml anti-coagulant acid citrate dextrose in the centrifugation sterile tube. The blood sample was then centrifuged using the centrifugation machine. 3 ml of PRP from the buffy coat layer were loaded in a 5 ml syringe. After local sterilization and draping of the site of injection and under US guidance the hematoma was aspirated from the injury site and the freshly prepared PRP was injected.
Study NCT05827484 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous platelets rich plasma + oral LOSARTAN administration
Description: in addition to local PRP injection, 50 mg / day of LOSARTAN (Cozaar® 50 mg film-coated tablets) were administrated to the study group orally every morning from day 5 and till day 30 after injury.
Study NCT04787952 — intervention group
Intervention type: OTHER
Intervention: cold expossure
Description: subjects were exposed for the cold, to activate and diagnose potential brown tissue activity
Study NCT04423159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OCV Vaccine
Description: 2 doses of OCV were administered to all enrolled participants 1st dose administered at baseline and second dose administered 28 days post 1st dose.
Study NCT02150772 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Shear Wave Elastography (SWE)
Study NCT01754818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendavia 10mg
Study NCT01754818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendavia 50mg
Study NCT03060642 — intervention group
Intervention type: DEVICE
Intervention: Electronic nose device
Description: Subjects breathe into the device, which then records an exhaled volatile organic compounds (VOC) signature.
Study NCT01754818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendavia 100mg
Study NCT01754818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02723929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active low-intensity transcranial electrical stimulation/active transcranial ultrasound
Description: Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for the full 20 minutes.
Study NCT02723929 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham low-intensity transcranial electrical stimulation/sham transcranial ultrasound
Description: Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation, as in the active condition; however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound in the same par. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.
Study NCT02749578 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Study NCT02749578 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MGL-3196
Study NCT00831415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained release tablets
Description: 25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.
Study NCT02329613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard evening meals.
Description: Patients will receive usual evening meals.
Study NCT02329613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved evening meal
Description: Patients will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.
Study NCT05502458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desﬂurane
Description: Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h. In the general anesthesia group with desflurane (group D), intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained with 4-6% desflurane. The analgesic and muscle relaxant regimens were the same in both groups except for sedative drugs. All patients were treated with no medication before operation, and the operation was completed under endotracheal intubation and general anesthesia. The amount of propofol or desflurane was adjusted according to BIS or MAC values and hemodynamic changes during operation. Add 10mg of rocuronium every half hour. Vasoactive drugs can be used to maintain hemodynamic stability during the operation, and corresponding records should be made
Study NCT05502458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h.
Study NCT01461655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marketed topical retinoid
Description: once daily application, 4 weeks
Study NCT01461655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marketed topical NSAID
Description: once daily application, 4 weeks
Study NCT01461655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: once daily application, 4 weeks
Study NCT01461655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: marketed topical retinoid
Description: once daily application, 4 weeks
Study NCT03804918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VitalTips mobile application
Description: VitalTips is a mobile learning application with learning on breaking bad news. Participants were expected to spend at least three hours using the mobile learning resource, ensuring that the time did not impact on their clinical and academic commitments.
Study NCT00779545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
Study NCT00779545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
Study NCT00779545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.
Study NCT00779545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
Study NCT00779545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
Study NCT00779545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
Study NCT00779545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
Study NCT03023280 — intervention group
Intervention type: PROCEDURE
Intervention: Radiofrequency ablation
Study NCT03208101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTP-HepB-IPV-Hib vaccine
Description: Hexavalent vaccine (DTP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Inactivated Poliovirus-Haemophilus influenzae type b vaccine)
Study NCT03208101 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP-HepB-Hib vaccine & IPV
Description: Pentavalent vaccine (DTP-HepB-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type b vaccine)+ IPV(Inactivated poliovirus vaccine)
Study NCT03763721 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative optical coherence tomography (iOCT)
Description: The OCT technology is fully integrated in a conventional ophthalmic surgical microscope (Zeiss LUMERA 700 platform). The OCT consists of A-scans (length/thickness) and B-scans (X-Y plane) to create the three dimensional image. Alternatively C-scans (3D cube scans) are available. All scans are non-invasive. The surgeon can continue surgery whilst using the iOCT and view a live image projected in the binocular or on the external screen and the video stream can be recorded as well.~The iOCT features are controlled using the foot paddle and the images are recorded on device. Investigations will be performed in a standardized matter: iOCT imagery and cube-scans after graft insertion, air injection, and the end of surgery.
Study NCT03763721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraoperative optical coherence tomography (iOCT)
Description: The OCT technology is fully integrated in a conventional ophthalmic surgical microscope (Zeiss LUMERA 700 platform). The OCT consists of A-scans (length/thickness) and B-scans (X-Y plane) to create the three dimensional image. Alternatively C-scans (3D cube scans) are available. All scans are non-invasive. The surgeon can continue surgery whilst using the iOCT and view a live image projected in the binocular or on the external screen and the video stream can be recorded as well.~The iOCT features are controlled using the foot paddle and the images are recorded on device. Investigations will be performed in a standardized matter: iOCT imagery and cube-scans after graft insertion, air injection, and the end of surgery.
Study NCT01829386 — intervention group
Intervention type: OTHER
Intervention: MRI scans with non heme iron levels
Description: MRI scans of the head will be performed to determine the amount of Non heme iron in areas of the brain of hemorrhagic stroke patients and hopefully predict the amount of brain damage.~Each MRI will take up to 1 hour to complete and will be done on day 3, day 14 and day 30. Some of the (MRIs) Magnetic Resonance Imaging will be clinically indicated and sequences will be added to the clinical scan with each sequence adding 10 minutes to the scan. Some sequences will be done only for research.
Study NCT01034943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External fixation
Description: Operation with external fixation and optional addition of k-wire
Study NCT01034943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar plate
Description: Operation with a Synthes volar two column plate (TCP)
Study NCT02311972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philips InnerSense Esophageal Temperature Sensor/Feeding Tube
Study NCT02311972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care feeding tube
Study NCT04333589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.
Study NCT00227682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ascorbic acid
Study NCT00227682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Study NCT00227682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00227682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study NCT01596751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
Study NCT01596751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
Study NCT03359460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT03359460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01460290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Asenapine will be administered open-label in pill form. Asenapine will be initiated at 5 mg twice a day and increased as tolerated to a maximum of 20 mg/day. It is anticipated that maximum stable dosing will be achieved by 4 weeks of treatment, although dosage may be reduced due to tolerability concerns at the discretion of the treating research psychiatrist.
Study NCT00978237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV
Description: one pill QD VO.
Study NCT00978237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: 2 pills QD VO
Study NCT02897622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Case management
Description: Case management by Eira unit
Study NCT01365637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: PF-05089771 will be dosed as a suspension twice daily
Study NCT01365637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: PF-05089771 will be dosed as a suspension either twice or thrice daily
Study NCT01754818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01345318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04236921
Description: Subjects entering this study will be given a 50 mg SC dose at baseline and then every 8 weeks through Week 40.
Study NCT01345318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04236921
Description: Dose escalation to 100 mg SC every 8 weeks will be allowed for subjects who have either not responded at Week 8 or have relapsed during the study.
Study NCT04715776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brown seaweed
Description: Uptake of 1650 mg brown seaweed product twice daily
Study NCT04715776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Uptake of 1650 mg placebo twice daily
Study NCT01577693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride
Description: novel dutasteride
Study NCT01577693 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dutasteride
Description: dutasteride soft gel capsule